Watchful Waiting

Reimbursement Support

Reimbursement Codes and Allowables

Reimbursement Guide

Radical Prostatectomy

Transurethral Resection of the Prostate (TURP)

Watchful Waiting

Benign Prostatic Hyperplasia (BPH)

Prostatitis

Helpful Links

Patient FAQs

Patient Information from Package Insert

Androgen Reduction Graph

Physician Information


	Bayer Global
	Bayer Corporate - USA

	general conditions of use privacy statement imprint © 2007 Bayer HealthCare Pharmaceuticals

Physician Support
Watchful Waiting

Viadur is indicated in the palliative treatment of advanced prostate cancer. Bayer is not responsible for, and does not endorse, any of the information found on this page.

Treatment Options


		Chemotherapy
		Cryosurgery
		Hormone therapy
		Radiation therapy
		Radical prostatectomy
		Transurethral resection of the prostate (TURP)
		Watchful waiting

There are many treatments for prostate cancer. The best one for you depends on a number of factors. These include your age, your overall health, and the stage and grade of your cancer.

Be sure to discuss the possible benefits, risks and side effects with each option. The sections here outline some of the general risks and side effects. However, your doctor is the best source of information on your condition. Before you and your doctor select any treatment approach, risks and benefits should be thoroughly discussed.Take the time to research all of your treatment options. Consider getting a second opinion before making a final decision. The most common treatment options for prostate cancer include watchful waiting, radiation, and hormone therapy.

"Watchful Waiting"

"Watchful Waiting" (also called expectant therapy) is not active treatment, but it may be a good choice for some men. Because prostate cancer often grows very slowly, older men who have the disease may not need treatment.¹ Your physician may suggest taking a watch and wait approach. This course of treatment will involve periodic examinations to determine if the cancer has become more aggressive. Active treatment can always be started later if the cancer begins to grow more rapidly or causes problems.²

What are possible side effects: When waiting and not pursuing active treatment of the cancer, it is possible that the cancer may spread beyond the prostate.

Who makes a good candidate: Men diagnosed with prostate cancer in their late 70s or 80s with a limited long-term life expectancy or men in their 60s and 70s with a limited long-term life expectancy.³

Viadur is indicated in the palliative treatment of advanced prostate cancer.

Printer-Friendly Version

References


	Important Safety Considerations Viadur is contraindicated in patients with hypersensitivity to Gn-RH, Gn-RH agonist analogs, or any of the components in Viadur. Viadur is contraindicated in women and pediatric patients and was not studied in women or children. Viadur, like other LH-RH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience a worsening of symptoms or onset of new symptoms including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, and spinal cord compression. The most comment systemic side effects were hot flashes (67.9%), asthenia (7.6%), gynecomastia (6.9%), depression (5.3%), and sweating (5.3%). The most common local side effects were bruising (34.6%) and burning (5.6%).
	Distributed and Marketed by:	Manufactured by:
	Bayer HealthCare Pharmaceuticals 6 West Belt, Wayne, NJ 07470 USA
	© Copyright 2007 Bayer HealthCare Pharmaceuticals. Viadur is a trademark of ALZA Corporation under license to Bayer HealthCare Pharmaceuticals. DUROS® is a registered trademark of ALZA Corporation. The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.